OCUL - one minor technical point that may be confusing to some, the article correctly reports that "On best corrected visual acuity, results looked similar between the two arms: there was a 1.3-letter decrease in the OTX-TKI arm, versus a 1.0-letter drop in the Eylea cohort, at seven months. Execs said that this sort of performance was to be expected, given that patients were being successfully treated with anti-VEGF therapy before enrolling."
It's my understanding that there are three measures of visual accuity, including EDTRS letter score (used in the OCUL trial) and what most of us are more familiar with the Snellen test (where "normal" vision is 20-20). The letter score ranges from 5 (at Snellen 20/800) to 85 (at Snellen 20/20). This website shows the equivalents.
The point is that if we have patients with, say, 20-40 Snellen or a 70 letter score, a change of 1 or 1.3 is pretty small and it is hard to believe a .3 difference could have any clinical meaning, and in the context of trial this small, it's just noise.
News 
Market Data 
Discover 
AI
